Cargando…

重型/极重型再生障碍性贫血患者红细胞寿命研究

OBJECTIVE: To explore the life span of red blood cells (RBC) in patients with severe/very severe aplastic anemia (SAA/VSAA). METHODS: Clinical data of 128 SAA/VSAA patients from November 2016 to April 2017 were retrospectively analyzed, and 13 healthy volunteers in the same period was used as normal...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342569/
https://www.ncbi.nlm.nih.gov/pubmed/29562449
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.02.012
_version_ 1783555526322290688
collection PubMed
description OBJECTIVE: To explore the life span of red blood cells (RBC) in patients with severe/very severe aplastic anemia (SAA/VSAA). METHODS: Clinical data of 128 SAA/VSAA patients from November 2016 to April 2017 were retrospectively analyzed, and 13 healthy volunteers in the same period was used as normal control. The endogenous Breath Carbon Monoxide (CO) test was used to detect the life span of RBC in SAA/VSAA patients, and the effect of immunosuppressive therapy (IST) on the life span of RBC in these patients was explored. RESULTS: The mean life span of RBC in 51 untreated SAA/VSAA patients was (50.69±21.43) d, which was significantly shorter than that in normal controls[(111.85±31.55) d](t=−6.611, P<0.001). The mean life span of RBC in 77 patients treated with IST was (87.14±39.28) d. The mean life span of RBC in complete responses (CR), hematologic response (HR) and non-response (NR) patients were (106.15±32.12) d, (92.00±38.60) d and (50.44±21.56) d, respectively. The life span of RBC in patients with HR was significantly longer than that in newly diagnosed and NR patients (t=7.430, P<0.001; t=4.846, P=0.002), which was similar to that in the normal controls (t=−1.743,P=0.085). There was no statistical significance between CR patients and the normal controls in the mean life span of RBC (t=−0.558, P=0.579). No factor affecting the RBC life span was found in univariate logistical regression analyses in the newly diagnosed SAA/VSAA patients. The serum levels of IL-2R and IL-6 were much lower in HR patients than NR patients[IL-2R: 4.3×10(5) U/L vs 6.5×10(5) U/L, z=−2.733, P=0.006; IL-6: 2.6 (2.0–17.7) ng/L vs 6.1 (2.0–14.4) ng/L, z=−2.968, P=0.003]. Of the 51 newly diagnosed patients, 38 received IST and their 3-month curative effect was evaluated. Receiver operator characteristics (ROC) curve was used to analyze the predictive effect of RBC life span of untreated patients on the efficacy of IST before treatment. The cut-off point was 60 days with sensitivity of 37.5% and specificity of 86.4%. In 9 cases with life span of RBC>60 d before IST, 6 cases acquired HR, while in 29 cases with life span of RBC≤60 d before IST, 10 cases acquired HR, the difference was not statistically significant (P=0.128). CONCLUSION: The life span of RBC in SAA/VSAA patients was shortened, which can be improved even recovered to the normal after IST. Elevated cytokines might play a role in the pathophysiology of the shortened RBC life span in SAA/VSAA.
format Online
Article
Text
id pubmed-7342569
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73425692020-07-16 重型/极重型再生障碍性贫血患者红细胞寿命研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the life span of red blood cells (RBC) in patients with severe/very severe aplastic anemia (SAA/VSAA). METHODS: Clinical data of 128 SAA/VSAA patients from November 2016 to April 2017 were retrospectively analyzed, and 13 healthy volunteers in the same period was used as normal control. The endogenous Breath Carbon Monoxide (CO) test was used to detect the life span of RBC in SAA/VSAA patients, and the effect of immunosuppressive therapy (IST) on the life span of RBC in these patients was explored. RESULTS: The mean life span of RBC in 51 untreated SAA/VSAA patients was (50.69±21.43) d, which was significantly shorter than that in normal controls[(111.85±31.55) d](t=−6.611, P<0.001). The mean life span of RBC in 77 patients treated with IST was (87.14±39.28) d. The mean life span of RBC in complete responses (CR), hematologic response (HR) and non-response (NR) patients were (106.15±32.12) d, (92.00±38.60) d and (50.44±21.56) d, respectively. The life span of RBC in patients with HR was significantly longer than that in newly diagnosed and NR patients (t=7.430, P<0.001; t=4.846, P=0.002), which was similar to that in the normal controls (t=−1.743,P=0.085). There was no statistical significance between CR patients and the normal controls in the mean life span of RBC (t=−0.558, P=0.579). No factor affecting the RBC life span was found in univariate logistical regression analyses in the newly diagnosed SAA/VSAA patients. The serum levels of IL-2R and IL-6 were much lower in HR patients than NR patients[IL-2R: 4.3×10(5) U/L vs 6.5×10(5) U/L, z=−2.733, P=0.006; IL-6: 2.6 (2.0–17.7) ng/L vs 6.1 (2.0–14.4) ng/L, z=−2.968, P=0.003]. Of the 51 newly diagnosed patients, 38 received IST and their 3-month curative effect was evaluated. Receiver operator characteristics (ROC) curve was used to analyze the predictive effect of RBC life span of untreated patients on the efficacy of IST before treatment. The cut-off point was 60 days with sensitivity of 37.5% and specificity of 86.4%. In 9 cases with life span of RBC>60 d before IST, 6 cases acquired HR, while in 29 cases with life span of RBC≤60 d before IST, 10 cases acquired HR, the difference was not statistically significant (P=0.128). CONCLUSION: The life span of RBC in SAA/VSAA patients was shortened, which can be improved even recovered to the normal after IST. Elevated cytokines might play a role in the pathophysiology of the shortened RBC life span in SAA/VSAA. Editorial office of Chinese Journal of Hematology 2018-02 /pmc/articles/PMC7342569/ /pubmed/29562449 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.02.012 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
重型/极重型再生障碍性贫血患者红细胞寿命研究
title 重型/极重型再生障碍性贫血患者红细胞寿命研究
title_full 重型/极重型再生障碍性贫血患者红细胞寿命研究
title_fullStr 重型/极重型再生障碍性贫血患者红细胞寿命研究
title_full_unstemmed 重型/极重型再生障碍性贫血患者红细胞寿命研究
title_short 重型/极重型再生障碍性贫血患者红细胞寿命研究
title_sort 重型/极重型再生障碍性贫血患者红细胞寿命研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342569/
https://www.ncbi.nlm.nih.gov/pubmed/29562449
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.02.012
work_keys_str_mv AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū
AT zhòngxíngjízhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhóngxìbāoshòumìngyánjiū